Merck KGaA's ERBITUX (cetuximab) Receives NMPA's Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
Shots:
- The approval is based on P-III CHANGE II study assessing extreme regimen (ERBITUX + cisplatin + 5-FU- followed by ERBITUX as maintenance therapy) vs Pt. based CT (cisplatin + 5-FU) in 243 patients aged ≥18 yrs. with R/M SCCHN- prior not treated with any systemic therapy in China
- The P-III CHANGE II study results: improvement in PFS (5.5 vs 4.2mos.); OS (10.2 vs 8.4mos.)- ORR (50% vs 27%) with no new safety findings
- ERBITUX is an IgG1 mAb targeting the EGFR and is an approved therapy in 100+ countries for RAS wild-type m-CRC and for HNSCC
Click here to read full press release/ article
Ref: Merck | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com